CUE-102 in Recurrent Glioblastoma

This study is testing an experimental cancer vaccine called CUE-102 in patients with recurrent glioblastoma (an aggressive brain tumor) that has come back after initial treatment. The vaccine is designed to activate the immune system to fight the cancer. **You may be eligible if...** - You are 18 or older with a Karnofsky performance score of 70 or higher (meaning you can care for yourself) - You have been diagnosed with Grade 4 glioblastoma or similar high-grade brain tumor at first recurrence - Your tumor carries a specific genetic marker (HLA-A*0201), determined by a blood test - You have completed prior chemotherapy and it has been at least 4 weeks since your last cycle - A recent brain MRI (within 14 days) shows stable or decreasing steroid use **You may NOT be eligible if...** - Your tumor is gliosarcoma - You have not yet received any prior treatment for your glioblastoma - You need high or increasing doses of steroids at the time of enrollment Talk to your doctor to see if this trial is right for you.